Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON (JNJ)

227
Delayed Quote. Delayed Nyse - 10/22 04:00:17 pm
101.22 USD   +0.86%
4h ago JOHNSON & JOHNSON : & to allocate $200 mln to Ebola vaccine production
8h agoDJU.S. HOT STOCKS : Hot Stocks to Watch
10h ago Glaxo's vaccine business undervalued - Schroders
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

05/16/2012 | 05:11am US/Eastern

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Latest news on JOHNSON & JOHNSON
2h ago JOHNSON & JOHNSON : J&J to sell 2 brands in India for 300 crore
3h ago JOHNSON & JOHNSON : Reports 2014 Third-Quarter Results:
4h ago JOHNSON & JOHNSON : Drugmakers to join forces to make millions of Ebola vaccine ..
4h ago JOHNSON & JOHNSON : & to allocate $200 mln to Ebola vaccine production
7h ago JOHNSON & JOHNSON : WHO: New Ebola treatment may be ready in two weeks
8h agoDJU.S. HOT STOCKS : Hot Stocks to Watch
10h ago Glaxo's vaccine business undervalued - Schroders
10h ago GLAXOSMITHKLINE : GSK sees first Ebola vaccine doses ready late this year
10h ago JOHNSON & JOHNSON : J&J to spend up to $200 million in push to speed up potentia..
10h ago JOHNSON & JOHNSON : J&J to spend up to $200M on Ebola vaccine program
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF